Global Antiviral Drugs Market Overview And Scope:
Global Antiviral Drugs Market Size was estimated at USD 42278.66 million in 2022 and is projected to reach USD 51470.15 million by 2028, exhibiting a CAGR of 3.33% during the forecast period.
The Global Antiviral Drugs Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Antiviral Drugs utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Roche, Johnson and Johnson, Merck, Novartis, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, AbbVie
Global Antiviral Drugs Market Segmentation
By Type, Antiviral Drugs market has been segmented into:Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Immune System Modulators
By Application, Antiviral Drugs market has been segmented into:
Hepatitis Therapeutics
HIV/AIDS Therapeutics
Herpes Therapeutics
Influenza Therapeutics
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Antiviral Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Antiviral Drugs market.
Top Key Players Covered in Antiviral Drugs market are:
Roche
Johnson and Johnson
Merck
Novartis
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
AbbVie
Objective to buy this Report:
1. Antiviral Drugs analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Antiviral Drugs market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Antiviral Drugs Market by Type
5.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
5.2 Antiviral Drugs Market Overview
5.3 Reverse Transcriptase Inhibitors
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Reverse Transcriptase Inhibitors: Geographic Segmentation
5.4 Protease Inhibitors
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Protease Inhibitors: Geographic Segmentation
5.5 Fusion Inhibitors
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Fusion Inhibitors: Geographic Segmentation
5.6 Immune System Modulators
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Immune System Modulators: Geographic Segmentation
Chapter 6: Antiviral Drugs Market by Application
6.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
6.2 Antiviral Drugs Market Overview
6.3 Hepatitis Therapeutics
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hepatitis Therapeutics: Geographic Segmentation
6.4 HIV/AIDS Therapeutics
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 HIV/AIDS Therapeutics: Geographic Segmentation
6.5 Herpes Therapeutics
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Herpes Therapeutics: Geographic Segmentation
6.6 Influenza Therapeutics
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Influenza Therapeutics: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Antiviral Drugs Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Antiviral Drugs Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Antiviral Drugs Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 ROCHE
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 JOHNSON AND JOHNSON
7.4 MERCK
7.5 NOVARTIS
7.6 BRISTOL-MYERS SQUIBB
7.7 GILEAD SCIENCES
7.8 GLAXOSMITHKLINE
7.9 ABBVIE
Chapter 8: Global Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Reverse Transcriptase Inhibitors
8.2.2 Protease Inhibitors
8.2.3 Fusion Inhibitors
8.2.4 Immune System Modulators
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hepatitis Therapeutics
8.3.2 HIV/AIDS Therapeutics
8.3.3 Herpes Therapeutics
8.3.4 Influenza Therapeutics
Chapter 9: North America Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Reverse Transcriptase Inhibitors
9.4.2 Protease Inhibitors
9.4.3 Fusion Inhibitors
9.4.4 Immune System Modulators
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hepatitis Therapeutics
9.5.2 HIV/AIDS Therapeutics
9.5.3 Herpes Therapeutics
9.5.4 Influenza Therapeutics
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Reverse Transcriptase Inhibitors
10.4.2 Protease Inhibitors
10.4.3 Fusion Inhibitors
10.4.4 Immune System Modulators
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hepatitis Therapeutics
10.5.2 HIV/AIDS Therapeutics
10.5.3 Herpes Therapeutics
10.5.4 Influenza Therapeutics
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Reverse Transcriptase Inhibitors
11.4.2 Protease Inhibitors
11.4.3 Fusion Inhibitors
11.4.4 Immune System Modulators
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hepatitis Therapeutics
11.5.2 HIV/AIDS Therapeutics
11.5.3 Herpes Therapeutics
11.5.4 Influenza Therapeutics
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Reverse Transcriptase Inhibitors
12.4.2 Protease Inhibitors
12.4.3 Fusion Inhibitors
12.4.4 Immune System Modulators
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hepatitis Therapeutics
12.5.2 HIV/AIDS Therapeutics
12.5.3 Herpes Therapeutics
12.5.4 Influenza Therapeutics
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Reverse Transcriptase Inhibitors
13.4.2 Protease Inhibitors
13.4.3 Fusion Inhibitors
13.4.4 Immune System Modulators
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hepatitis Therapeutics
13.5.2 HIV/AIDS Therapeutics
13.5.3 Herpes Therapeutics
13.5.4 Influenza Therapeutics
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Reverse Transcriptase Inhibitors
14.4.2 Protease Inhibitors
14.4.3 Fusion Inhibitors
14.4.4 Immune System Modulators
14.5 Historic and Forecasted Market Size By Application
14.5.1 Hepatitis Therapeutics
14.5.2 HIV/AIDS Therapeutics
14.5.3 Herpes Therapeutics
14.5.4 Influenza Therapeutics
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Antiviral Drugs Scope:
|
Report Data
|
Antiviral Drugs Market
|
|
Antiviral Drugs Market Size in 2025
|
USD XX million
|
|
Antiviral Drugs CAGR 2025 - 2032
|
XX%
|
|
Antiviral Drugs Base Year
|
2024
|
|
Antiviral Drugs Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Roche, Johnson and Johnson, Merck, Novartis, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, AbbVie.
|
|
Key Segments
|
By Type
Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Immune System Modulators
By Applications
Hepatitis Therapeutics
HIV/AIDS Therapeutics
Herpes Therapeutics
Influenza Therapeutics
|
